JBCHEPHARM - Technical Analysis with Chart Patterns & Indicators

Last Updated Time : 05 Nov 25, 7:43 am

Technical Rating: 3.9

📈 JBCHEPHARM is consolidating with mild bullish momentum and strong fundamentals, supported by institutional accumulation and improving earnings.

📊 Technical Analysis

• Trend Status: Consolidating — price is hovering around both 50-DMA and 200-DMA, indicating indecision.
• Moving Averages: Price ₹1,712 is slightly above 50-DMA (₹1,693) and 200-DMA (₹1,696), suggesting mild bullish bias.
• RSI (47.2): Neutral zone, indicating balanced momentum with no strong directional signal.
• MACD (0.95): Bullish crossover, hinting at potential upward movement.
• Bollinger Bands: Price near mid-band, consistent with consolidation and low volatility.
• Volume: Current volume (1.64L) is above weekly average (1.04L), showing increased participation.

🎯 Entry & Exit Zones

• Support Levels: ₹1,693 (50-DMA), ₹1,650, ₹1,600
• Resistance Levels: ₹1,750, ₹1,800, ₹1,850
• Optimal Entry: ₹1,690–₹1,710 (on pullback)
• Exit Target: ₹1,800–₹1,850 (resistance zone)

✅ Positive

• ROCE (25.9%) and ROE (20.2%) reflect strong capital efficiency.
• EPS of ₹43.5 and quarterly PAT growth from ₹150 Cr to ₹198 Cr show earnings momentum.
• DII holdings increased by 3.21%, indicating strong domestic institutional interest.
• Debt-to-equity ratio of 0.00 highlights excellent financial health.

⚠️ Limitation

• RSI below 50 suggests limited momentum strength.
• MACD is positive but not strongly divergent, indicating mild momentum.
• PEG ratio of 1.66 suggests moderate overvaluation relative to growth.

📉 Company Negative News

• FII holdings declined by 2.46%, showing reduced foreign investor confidence.
• Stock is down 12.4% from its 52-week high of ₹1,955, reflecting recent correction.

📈 Company Positive News

• Quarterly profit variation of 14.2% reflects operational improvement.
• Price has gained 31.4% from its 52-week low of ₹1,303.

🏭 Industry

• Pharmaceutical sector remains resilient with consistent demand and innovation-driven growth.
• Industry P/E (33.1) is slightly lower than JBCHEPHARM’s (39.6), suggesting premium valuation.

🧾 Conclusion

• JBCHEPHARM is consolidating with mild bullish signals and strong financial fundamentals.
• Entry near ₹1,690–₹1,710 could offer a tactical setup with targets around ₹1,800–₹1,850.
• Investors should monitor RSI and MACD for signs of breakout or reversal confirmation.